CureVac Presents Results of a Phase I/IIa Trial in Non-Small Cell Lung Cancer (NSCLC) with CV9201, an mRNA Based Cancer Vaccine, at the 26th Annual SITC Meeting in Washington
|| Print ||
|Monday, 07 November 2011 09:15 (UTC + 1)|
Tübingen, Germany, November 7, 2011/ B3C newswire / – CureVac GmbH, the mRNA vaccine company, yesterday presented the results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC) with CV9201, an mRNA-based cancer vaccine, in patients with NSCLC stage IIIB/IV after first-line chemo-radiotherapy or chemotherapy, respectively. The trial strived to assess safety and toxicity of CV9201 as well as its ability to induce antigen-specific humoral and cellular immune responses in cancer patients. The results suggest that CV9201 is safe, well tolerated and biologically active. The trial evaluated a five dose regime of CV9201 delivered via intradermal injection in 46 patients.
The trial with CV9201, conducted in
The results of the NSCLC trial underpin the broad applicability of CureVac’s proprietary RNActive® vaccination technology to generate novel cancer vaccines against tumor-associated antigens. The results are seen as another important validation step of CureVac’s innovative proprietary RNActive® vaccination technology.
Dr. Ingmar Hoerr, CEO of CureVac, said “I believe these new results are excellent news for patients. We are eager to further investigate our RNActive® vaccination technology in oncology. In fact, CureVac´s RNActive® vaccination technology could represent a real step forward in the effort to develop disease specific or even patient specific cancer immunotherapies.”
CureVac´s RNActive® tumor immunotherapy approach is independent of the HLA subtype. CV9201 is one candidate in CureVac’s pipeline of RNActive®-derived molecules for the active immunotherapy of cancer. The vaccine comprises mRNA molecules encoding five different antigens of which three are cancer testis antigens.